SEC Form 10-Q Summary
Filing-period note: The request identifies Cartesian Therapeutics, Inc., but the supplied Form 10-Q is for Selecta Biosciences, Inc. for the quarter ended June 30, 2018. Investors should verify the issuer before relying on this summary.
Business Context and Reporting Period
Selecta was a clinical-stage biopharmaceutical company developing synthetic vaccine particle technology intended to modulate immune responses. Its lead candidate was SEL-212 for chronic severe gout. Other programs included SEL-403 for mesothelioma, SELA-070 for smoking cessation, and preclinical gene therapy candidates SEL-302 and SEL-313. The company had no approved products or product sales and generated revenue only from grants and collaboration agreements.
The unaudited interim financial statements cover the three and six months ended June 30, 2018, with comparisons to the corresponding 2017 periods. The company adopted ASC 606 revenue guidance on January 1, 2018 using the modified retrospective method.
Financial Metrics
| Metric | Three Months Ended June 30, 2018 | Three Months Ended June 30, 2017 | Six Months Ended June 30, 2018 | Six Months Ended June 30, 2017 |
|---|---|---|---|---|
| Revenue | $0.0 million | $0.026 million | $0.0 million | $0.163 million |
| Research and development expense | $14.407 million | $10.994 million | $25.546 million | $22.038 million |
| General and administrative expense | $4.362 million | $4.903 million | $9.036 million | $8.778 million |
| Net loss | $18.796 million | $15.967 million | $34.684 million | $31.101 million |
| Net loss per share | $0.84 | $0.85 | $1.55 | $1.67 |
| Net cash used in operating activities | Not separately presented | $30.382 million | $23.930 million |
As of June 30, 2018, cash, cash equivalents, restricted cash, and short-term investments totaled approximately $66.2 million, compared with $96.6 million at December 31, 2017. Total assets were $73.4 million, total liabilities were $49.2 million, and stockholders’ equity was $24.3 million. The accumulated deficit was $247.2 million.
Outstanding debt consisted principally of a $21.0 million SVB term loan, reported as a $21.2 million loan payable after debt discount and deferred charges. The loan matures in February 2022, has interest-only payments through August 2019, is secured by substantially all assets other than intellectual property, and contains no financial covenants or minimum cash requirement.
Material Changes Versus the Prior Comparable Period
- Revenue declined to zero from $0.026 million in the second quarter and $0.163 million in the first six months of 2017.
- Second-quarter research and development expense increased 31% to $14.4 million; six-month expense increased 16% to $25.5 million, primarily because of SEL-212 Phase 2 activity and Phase 3 planning.
- Second-quarter general and administrative expense decreased 11% to $4.4 million, while six-month expense increased 3% to $9.0 million.
- Six-month net loss increased to $34.7 million from $31.1 million, although loss per share improved to $1.55 from $1.67 because of a larger share base.
- Operating cash burn increased to $30.4 million from $23.9 million. The company had only $0.4 million of financing cash inflows in 2018, compared with $53.7 million in 2017, which included the $50.0 million private placement.
- Investing activities provided $19.6 million in 2018, principally from investment maturities, compared with $5.8 million of cash used in 2017.
- ASC 606 adoption reduced opening deferred revenue by $1.8 million and increased opening accumulated deficit by $4.4 million, principally due to revised treatment of the Spark and Skolkovo arrangements. The filing states that adoption did not change reported 2018 operating results.
Guidance, Outlook, Risks, and Unusual Items
Management expected existing cash, cash equivalents, and short-term investments as of June 30, 2018 to fund operating and capital requirements through the end of the third quarter of 2019. This estimate included preparation for SEL-212 Phase 3 and initial enrollment at a limited number of sites, but did not fund expanded Phase 3 enrollment or the planned head-to-head trial against Krystexxa. Additional equity or other external financing was expected to be required.
The company planned to initiate the SEL-212 head-to-head trial in parallel with the Phase 3 program and expected clinical data at three- and six-month time points in 2019. The filing cautions that the funding runway depends on assumptions that may prove incorrect and that clinical timing, enrollment, regulatory requirements, manufacturing, and development costs could cause cash to be used sooner.
- The company expected continuing and potentially increasing operating losses and had no committed external source of liquidity other than potential collaboration and grant funding.
- SEL-212 depended substantially on third-party manufacturing, including 3SBio in China as the primary supplier of pegsiticase. Regulatory approval, supply continuity, quality, and manufacturing scale-up remained significant risks.
- The company disclosed multiple serious adverse events in the SEL-212 Phase 1/2 program and emphasized the uncertainty of clinical efficacy, safety, enrollment, and FDA requirements.
- The Skolkovo grant was discontinued during the quarter. Skolkovo required the company to return less than $0.1 million of unused funds and reimburse $0.1 million of costs deemed overspent. A $0.1 million contract liability remained subject to the audit period.
- Contract liabilities totaled $16.9 million at June 30, 2018, including $14.8 million of deferred revenue and $2.1 million of other liabilities, primarily associated with the Spark reimbursement arrangement.
- The CEO announced retirement effective December 31, 2018, and the chief medical officer announced retirement effective January 1, 2019, creating executive-transition risk.
- The company had no material legal proceedings and no off-balance-sheet arrangements. Management concluded disclosure controls were effective as of June 30, 2018.
Most Important Facts for Investors to Verify
- Confirm that the filing belongs to Selecta Biosciences, Inc., not Cartesian Therapeutics, Inc.
- Verify the timing and terms of any financing needed to fund expanded SEL-212 Phase 3 enrollment and the Krystexxa head-to-head trial.
- Track SEL-212 clinical results, serious adverse events, enrollment, FDA feedback, and Phase 3 initiation.
- Assess the company’s cash runway against actual quarterly operating cash burn and research and development spending.
- Review the SVB loan’s collateral, acceleration provisions, interest-rate exposure, and repayment schedule.
- Monitor manufacturing and regulatory developments involving 3SBio and other contract manufacturers.
- Evaluate the effect of the ASC 606 adoption and the collectability or potential repayment of Skolkovo and Spark-related contract balances.
- Follow the CEO and chief medical officer succession process and its potential effect on clinical execution.